Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

OBJECTIVE: This study aimed to evaluate the safety of avacopan, an orally administered C5a receptor inhibitor, for the treatment of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis in addition to standard‐of‐care (SOC) treatment with glucocorticoids with cyclophosphamide or rituximab...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:ACR Open Rheumatol
Prif Awduron: Merkel, Peter A., Niles, John, Jimenez, Richard, Spiera, Robert F., Rovin, Brad H., Bomback, Andrew, Pagnoux, Christian, Potarca, Antonia, Schall, Thomas J., Bekker, Pirow
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2020
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7672305/
https://ncbi.nlm.nih.gov/pubmed/33128347
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acr2.11185
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg